MoneyWorks4Me

Bajaj Healthcare informs about press release

04 Oct 2025 Evaluate
Bajaj Healthcare has informed that the company has received recommendation from Subject Expert Committee (SEC) (Neurology & Psychiatry) of Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Suvorexant Tablets 5mg, 10mg, 50mg, 15mg & 20mg. The press release in this regard, being issued by the Company is submitted.

The above information is a part of company’s filings submitted to BSE. 
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..